Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Treatment of smoldering multiple myeloma

Nature Reviews Clinical Oncology volume 10, page 724 (2013)Cite this article

Subjects

We read with interest the News & Views article by Rajkumar and Kyle (Treatment of smoldering multiple myeloma. Nat. Rev. Clin. Oncol. 10, 554–555; 2013)1 that focused on a recently published study by Mateos and colleagues.2 We agree with Rajkumar and Kyle that additional studies are needed to determine the patients with SMM who would benefit from early treatment.1 However, although treatment of a tumour at an early stage is, of course, ideal in attempting to achieve a cure, many questions arise from the underlying study2 and we would like to raise some further points of discussion not conveyed in the recent editorial.

We mainly argue that the treatment groups were unbalanced in the intensity of treatment received. When comparing the SMM treatment and observation groups, a clear advantage in overall survival must be seen.1,2 This advantage is related not only to safety and quality-of-life issues for the patient, but is also relevant in terms of understanding the cost effectiveness of treatments. Experimental treatment must be superior in terms of overall survival, either to the gold standard treatment at disease progression (for that population stratified by age), or should be the same treatment for both groups (type and duration). In other words, to demonstrate an advantage for early treatment, the only variable should be the time of treatment initiation (early versus late). In the study by Mateos and colleagues, treatment duration with lenalidomide was almost 3 years (9 months induction + 2 years of maintenance) versus a shorter duration that was not clearly specified in the study for the observation group. It seems, therefore, that patients in the treatment group received consolidation and maintenance with lenalidomide that was not given to the observation group, representing a bias for the study.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Rajkumar, S. V. & Kyle, R. A. Treatment of smoldering multiple myeloma. Nat. Rev. Clin. Oncol. 10, 554–555 (2013).

    Article  CAS  Google Scholar 

  2. Mateos, M. V. et al. Lenalidomide plus dexamethasone for high risk smoldering multiple myeloma. N. Engl. J. Med. 369, 438–447 (2013).

    Article  CAS  Google Scholar 

  3. Rajkumar, S. V. et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 27, 1738–1744 (2013).

    Article  CAS  Google Scholar 

  4. Gozzetti, A. & Le Beau, M. M. Fluorescence in situ hybridization: uses and limitations. Semin. Hematol. 37, 320–333 (2000).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank Siena A.I.L. (The Italian association against leukemia, lymphoma and myeloma, Siena district, Italy), and all of the doctors, nurses and laboratory technicians who work at the Division of Hematology and Transplants at the Azienda Ospedaliera Universitaria Senese, Siena, Italy, for their daily help in patient care.

Author information

Authors and Affiliations

  1. Division of Haematology and Transplants, University of Siena, Policlinico “Santa Maria alle Scotte”, Viale Bracci 16, Siena, 53100, Italy

    Alessandro Gozzetti, Marzia Defina & Monica Bocchia

Authors
  1. Alessandro Gozzetti
    View author publications

    Search author on:PubMed Google Scholar

  2. Marzia Defina
    View author publications

    Search author on:PubMed Google Scholar

  3. Monica Bocchia
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Alessandro Gozzetti.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gozzetti, A., Defina, M. & Bocchia, M. Treatment of smoldering multiple myeloma. Nat Rev Clin Oncol 10, 724 (2013). https://doi.org/10.1038/nrclinonc.2013.160-c1

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.160-c1

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer